FDA
Categories
Conferences
- AACR
- ASCO
- SABCS
- ASH
- MOASC
About
Contact
Advertise

Advertisement

X (Twitter) LinkedIn Facebook

X (Twitter) LinkedIn Facebook YouTube

FDA
Categories
Conferences
- AACR
- ASCO
- SABCS
- ASH
- MOASC
About
Contact
Advertise

Home » The benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

Non-Small Cell Lung Cancer

The benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

By EditorJuly 18, 2018No Comments1 Min Read

Twitter LinkedIn Facebook Email

Share

Twitter LinkedIn Facebook Email

Roy S. Herbst, MD, PhD, explains the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC at Annual Meeting 2018.

Follow on X (Twitter) Follow on LinkedIn Follow on Facebook Follow on Google News

Share. Twitter LinkedIn Facebook Email

Related Posts

FDA Grants Priority Review Zongertinib for HER2-Mutant NSCLC | Breakthrough in Lung Cancer Treatment

Non-Small Cell Lung Cancer 5 Mins Read

Plasma ctDNA Kinetics as a Predictor of Systemic Therapy Response in Advanced NSCLC

Non-Small Cell Lung Cancer 3 Mins Read

VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024

Non-Small Cell Lung Cancer 2 Mins Read

Advertisement

Recent Posts

AACR – Douglas Hanahan, PhD, FAACR, Receives 2025 Pezcoller-AACR Award for Cancer Research Excellence
Immunotherapy Side Effects Under Scrutiny: New Data on Bone Density and T-Cell Insights
FDA Approves TEVIMBRA for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
Renal Cell Carcinoma TiNivo-2 Study: Patient-Reported Outcomes in Treatment Post-ICI
FDA Grants Priority Review Zongertinib for HER2-Mutant NSCLC | Breakthrough in Lung Cancer Treatment

Connect With Us on Social

Facebook
Twitter
LinkedIn
YouTube

Donate

Advertise On OncologyTube.com

X (Twitter) LinkedIn Facebook

FDA
Categories
Conferences
- AACR
- ASCO
- SABCS
- ASH
- MOASC
About
Contact
Advertise

© 2025 Copyright Protected Medicus Networks, Inc..

Type above and press Enter to search. Press Esc to cancel.

×